Moleculin Biotech, Inc.

Moleculin Biotech is a late-stage pharmaceutical development company focused on creating treatments for hard-to-treat oncology indications and viruses. The company's lead drug candidate is Annamycin, a next-generation anthracycline designed to avoid cardiotoxicity and bypass multidrug resistance mechanisms. Its clinical pipeline also includes the WP1066 program targeting glioblastoma and other brain tumors, as well as the WP1122 portfolio of glycolysis inhibitors. Core clinical candidates serve patient populations with acute myeloid leukemia, soft tissue sarcoma lung metastases, and pediatric brain cancers.

The company operates internationally, coordinating research and clinical programs across academic institutions and medical centers in the United States and Europe. Its clinical trials include multi-center evaluations spanning over twenty sites across nine countries, such as Poland, Italy, and the United States. Key preclinical and development collaborations take place in conjunction with the University of Texas MD Anderson Cancer Center in Houston, Texas. Moleculin Biotech does not specify its corporate headquarters location in the provided text.

Summary of the business section of Moleculin Biotech's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“There are approximately 150,000 people with AML worldwide with over 20,000 newly diagnosed patients annually in the U.S.”